Anuh Pharma Ltd
₹ 79.0
-1.41%
17 Jul
- close price
About
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Key Points
- Market Cap ₹ 792 Cr.
- Current Price ₹ 79.0
- High / Low ₹ 108 / 66.7
- Stock P/E 19.3
- Book Value ₹ 35.1
- Dividend Yield 1.90 %
- ROCE 15.9 %
- ROE 12.1 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 24.4%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | |
| 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 710 | |
| Operating Profit | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 62 |
| OPM % | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% |
| 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 4 | |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 |
| Profit before tax | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 |
| Tax % | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | 24% |
| 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | |
| EPS in Rs | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.10 |
| Dividend Payout % | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% | 37% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 13% |
| 3 Years: | 8% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 16% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 15% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 |
| 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 | |
| 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 205 | |
| Total Liabilities | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
| 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 | |
| CWIP | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 |
| 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 416 | |
| Total Assets | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 | |
| -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 | |
| -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 | |
| Net Cash Flow | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -12 |
| Free Cash Flow | 18 | 6 | 25 | -5 | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| CFO/OP | 96% | 78% | 149% | 49% | 56% | 232% | -20% | 80% | 130% | 42% | 78% | 17% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 | 113 |
| Inventory Days | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days Payable | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash Conversion Cycle | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 | 89 |
| Working Capital Days | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 | 114 |
| ROCE % | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% | 16% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity MTPA |
|
||||||||||
| Export Revenue Share % |
|||||||||||
| Number of Countries (Export Reach) count |
|||||||||||
| Number of Customers count |
|||||||||||
| Total Production Volume MT |
|||||||||||
| Capacity Utilization % |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jul - Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026 received from Bigshare Services Private …
- Closure of Trading Window 26 Jun
- Clarification For Newspaper Publication 20 Jun
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 (''''SEBI LODR'''')
19 Jun - Income Tax Department imposed Rs. 17.46 lakh demand and penalty for AY 2020-21; company will appeal.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Jun - Newspaper Publication for transfer of equity shares of the Company for which Dividend has not been claimed by shareholders for seven consecutive years or more …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Dec 2017TranscriptAI SummaryPPT
-
Feb 2016TranscriptAI SummaryPPT
-
Dec 2015TranscriptAI SummaryPPT
-
Sep 2015TranscriptAI SummaryPPT
-
Aug 2015TranscriptAI SummaryPPT
Part of SK Group of companies:[1]
The company is a bulk drug manufacturing company, and is part of the Rs. 8.5 billion SK Group. SK Group employs approximately 2,200 people across businesses including pharmaceutical formulations manufacturing, Trading, Distribution and Logistics (primarily for large MNC brands).